Genentech, Inc.
NEWS
Genentech’s flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
Genentech (Roche) reported Wednesday that its Phase III SKYSCRAPER-01 trial failed to meet its co-primary endpoint of progression-free survival (PFS).
A roundup of last week’s top clinical trial updates and news.
The U.S. FDA’s Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.
Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Genentech (Roche)’s Avastin.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
Interim data from Genentech’s first randomized study on a candidate treatment for extensive-stage small-cell lung cancer failed to meet its co-primary endpoint.
The study suggests that artificial sweeteners, which are readily available in coffee shops and used in diet soft drinks, increase the risks of breast cancer and obesity.
JOBS
IN THE PRESS